Please use this identifier to cite or link to this item:
Title: Biodegradable polymeric nanocapsules prevent cardiotoxicity of anti-trypanosomal lychnopholide.
Authors: Branquinho, Renata Tupinambá
Roy, Jérôme
Farah, Charlotte
Garcia, Giani Martins
Aimond, Franck
Guennec, Jean Yves Le
Guimarães, Dênia Antunes Saúde
Guimarães, Andrea Grabe
Mosqueira, Vanessa Carla Furtado
Lana, Marta de
Richard, Sylvain
Issue Date: 2017
Citation: BRANQUINHO, R. T. et al. Biodegradable polymeric nanocapsules prevent cardiotoxicity of anti-trypanosomal lychnopholide. Scientific Reports, v. 7, p. 44998, 2017. Disponível em: <>. Acesso em: 29 ago. 2017.
Abstract: Chagas disease is a neglected parasitic disease caused by the protozoan Trypanosoma cruzi. New antitrypanosomal options are desirable to prevent complications, including a high rate of cardiomyopathy. Recently, a natural substance, lychnopholide, has shown therapeutic potential, especially when encapsulated in biodegradable polymeric nanocapsules. However, little is known regarding possible adverse effects of lychnopholide. Here we show that repeated-dose intravenous administration of free lychnopholide (2.0 mg/kg/day) for 20 days caused cardiopathy and mortality in healthy C57BL/6 mice. Echocardiography revealed concentric left ventricular hypertrophy with preserved ejection fraction, diastolic dysfunction and chamber dilatation at end-stage. Single cardiomyocytes presented altered contractility and Ca2+ handling, with spontaneous Ca2+ waves in diastole. Acute in vitro lychnopholide application on cardiomyocytes from healthy mice also induced Ca2+ handling alterations with abnormal RyR2-mediated diastolic Ca2+ release. Strikingly, the encapsulation of lychnopholide prevented the cardiac alterations induced in vivo by the free form repeated doses. Nanocapsules alone had no adverse cardiac effects. Altogether, our data establish lychnopholide presented in nanocapsule form more firmly as a promising new drug candidate to cure Chagas disease with minimal cardiotoxicity. Our study also highlights the potential of nanotechnology not only to improve the efficacy of a drug but also to protect against its adverse effects.
ISSN: 2045-2322
metadata.dc.rights.license: This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit Fonte: o próprio artigo.
Appears in Collections:DEACL - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
ARTIGO_BiodegradablePolymericNanocapsules.pdf2,11 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.